Effects of aspirin when added to the prostaglandin d2 receptor antagonist laropiprant on niacin-induced flushing symptoms

Journal of Clinical Pharmacology

Volumn 49, Issue 4, 2009, Pages 416-422

  Dishy, Victor ^a   Liu, Fang ^b   Ebel, David L ^b   Atiee, George J ^c,f   Royalty, Jane ^d   Reilley, Sandra ^e   Paolini, John F ^b   Wagner, John A ^b   Lai, Eseng ^b,f  

^a DAIICHI SANKYO INC   (United States)

^b Department of Clinical Pharmacology ^*

^c Healthcare Discoveries Inc   (United States)

^d Department of Clinical Biostatistics and Decision Sciences ^*  (United States)

^e Northwest Kinetics   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Aspirin; Atherosclerosis; DP1; Flushing; Laropiprant

Indexed keywords

ACETYLSALICYLIC ACID; LAROPIPRANT; NICOTINIC ACID; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FLUSHING; GASTROENTERITIS; HUMAN; HYPERGLYCEMIA; HYPOTENSION; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SELF EVALUATION; SIDE EFFECT; SYMPTOMATOLOGY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTILIPEMIC AGENTS; ASPIRIN; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FLUSHING; HUMANS; INDOLES; MALE; MIDDLE AGED; NIACIN; PLACEBOS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN;

EID: 63849228890     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009332246     Document Type: Article

References (25)

1. Baigent C., Keech A., Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267-1278.
2. Gotto AM Jr. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J. 2002; 144: S33 - S42.
3. Abdel-Maksoud MF, Hokanson JE The complex role of triglycerides in cardiovascular disease. Semin Vasc Med. 2002; 2: 325-333.
4. Singh IM, Shishehbor MH, Ansell BJ High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007; 298: 786-798.
5. Barter P., Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007; 357: 1301-1310.
6. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol. 1998; 82: 74U - 81U.
7. Canner PL, Furberg CD, McGovern ME Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol. 2006; 97: 477-479.
8. Cashin-Hemphill L., Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA. 1990; 264: 3013-3017.
9. Brown G., Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990; 323: 1289-1298.
10. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004; 110: 3512-3517.
11. Guyton JR, Bays HE Safety considerations with niacin therapy. Am J Cardiol. 2007; 99: 22C - 31C.
12. Dunn RT, Ford MA, Rindone JP, Kwiecinski FA Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther. 1995; 2: 478-480.
13. Jungnickel PW, Maloley PA, Vander Tuin EL, Peddicord TE, Campbell JR Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med. 1997; 12: 591-596.
14. Oberwittler H., Baccara-Dinet M. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. Int J Clin Pract. 2006; 60: 707-715.
15. Whelan AM, Price SO, Fowler SF, Hainer BL The effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract. 1992; 34: 165-168.
16. Wilkin JK, Wilkin O., Kapp R., Donachie R., Chernosky ME, Buckner J. Aspirin blocks nicotinic acid-induced flushing. Clin Pharmacol Ther. 1982; 31: 478-482.
17. Knopp RH, Alagona P., Davidson M., et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 1998; 47: 1097-1104.
18. Morgan JM, Capuzzi DM, Guyton JR A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol. 1998; 82: 29U - 34U.
19. Vogt A., Kassner U., Hostalek U., Steinhagen-Thiessen E. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. Curr Med Res Opin. 2006; 22: 417-425.
20. Cheng K., Wu TJ, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci USA. 2006; 103: 6682-6687.
21. Lai E., De Lepeleire I., Crumley TM, et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther. 2007; 81: 849-857.
22. Lai E., Wenning LA, Crumley TM, et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D(2) receptor antagonist. Clin Pharmacol Ther. 2008; 83: 840-847.
23. Paolini JF, Mitchel YB, Reyes R., et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008; 101: 625-630.
24. Benyo Z., Gille A., Kero J., et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest. 2005; 115: 3634-3640.
25. Norquist JM, Watson DJ, Yu Q., Paolini JF, McQuarrie K., Santanello NC Validation of a questionnaire to assess niacin-induced cutaneous flushing. Curr Med Res Opin. 2007; 23: 1549-1560.